Raddeanin A exerts potent efficacy against non-small cell lung cancer by inhibiting cyclin-dependent kinase 6
Raddeanin A blocks the cell cycle in G1 phase by inhibiting CDK6. Raddeanin A is expected to be a novel antitumor agent against NSCLC.
Authors
- Mengchu Liu
- Xiao Lin (ORCID: https://orcid.org/0000-0003-3794-346X)
- Yi-Han Ye (ORCID: https://orcid.org/0000-0001-8366-2947)
- Jiayu Bai
- Xiaoying Huang (ORCID: https://orcid.org/0000-0003-4854-0922)
- Chunbo Ma (ORCID: https://orcid.org/0009-0005-3324-6511)
- Xian Wang (ORCID: https://orcid.org/0000-0003-0041-7589)
- Yuxin Liu (ORCID: https://orcid.org/0000-0002-8632-2910)
- Liangxing Wang (ORCID: https://orcid.org/0000-0002-1312-9554)
- Lehe Yang (ORCID: https://orcid.org/0000-0002-9120-0731)
- Chengguang Zhao (ORCID: https://orcid.org/0000-0002-9981-0200)
Institutions
- Wenzhou Medical University (CN)
- First Affiliated Hospital of Wenzhou Medical University (CN)
Publication Details
- Journal
- Translational Oncology
- Published
- 2025-04-11
- DOI
- https://doi.org/10.1016/j.tranon.2025.102382
- Citations
- 2
- Primary Topic
- Cancer-related Molecular Pathways
- Type
- article
- Field-Weighted Citation Impact
- 2.09